Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...
Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer. The selective oral CDK4/6 ...
This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...
Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due ...
Erica S. Doubleday, MS, FNP-C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer. Monitoring patients’ symptoms across ...
Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including ...
Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, ...
Addressing Neurologic Toxicities in CAR-T Therapy: Monitoring, Management, and Patient Communication
Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that ...
Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, ...
Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on ...
Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback